Welcome to our dedicated page for bli news (Ticker: bli), a resource for investors and traders seeking the latest updates and insights on bli stock.
Berkeley Lights, Inc. operates as a leading biotechnology company dedicated to providing cutting-edge technology solutions for single-cell manipulation. The company's innovative platform facilitates advancements in biopharma, diagnostics, and life science research. Berkeley Lights leverages its proprietary OptoSelect™ technology to enable precise control over biological processes at the single-cell level.
Headquartered in the United States, Berkeley Lights serves a global customer base, including leading pharmaceutical companies, research institutions, and diagnostics firms. The company's technology empowers researchers to discover new drugs, create better diagnostics, and develop innovative therapies.
One of the notable recent achievements of Berkeley Lights is the expansion of its platform capabilities, enhancing the efficiency and accuracy of single-cell analysis. The company has also formed strategic partnerships with key industry players to drive further innovation and market reach.
Financially, Berkeley Lights continues to show robust performance, with steady revenue growth and strategic investments in research and development. The company is committed to maintaining a strong financial position to support its mission of advancing human health through groundbreaking biotechnological solutions.
Current projects include the development of advanced cell therapy applications and expanding the use of their technology in various research and clinical settings. These projects highlight Berkeley Lights' commitment to pushing the boundaries of what's possible in biotechnology.
Overall, Berkeley Lights, Inc. stands at the forefront of biotechnology, offering unparalleled solutions for single-cell research and manipulation. The company's dedication to innovation and quality makes it a significant player in the life sciences sector.
Berkeley Lights, Inc. (BLI) reported a 35% increase in revenue for Q1 2021, totaling $18.6 million. The company expanded its installed base to 85 platforms and launched Opto Assure, enhancing product quality assessment in cell development. Despite strong revenue growth, operating losses increased to $15.1 million, up from $8.2 million in Q1 2020, impacting net loss per share, which was $(0.24). The company anticipates full-year revenue between $90 million and $100 million, indicating an annual growth of 40% to 56%.
Berkeley Lights, Inc. (BLI) announced leadership changes, appointing Gregory T. Lucier as the new Chairperson of the Board, effective May 14, 2021, succeeding Michael Marks, who is retiring. John Chiminski, CEO of Catalent, joins the Board as an Independent Director. Lucier aims to advance Berkeley Lights' mission in digital cell biology, while Chiminski expresses enthusiasm for the company's growth potential. CEO Eric Hobbs praised both leaders for their extensive experience in life sciences. Marks was acknowledged for his key contributions during the company's transition to a public entity.
Berkeley Lights, Inc. (Nasdaq: BLI) will report its first quarter 2021 financial results on May 11, 2021, before market open. The management will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET, which can be accessed via the company's website. The company specializes in digital cell biology, focusing on the rapid development of biotherapeutics. Its platform, which includes proprietary consumables and advanced automation systems, aims to establish industry standards for cell-based product development.
Berkeley Lights, Inc. (Nasdaq: BLI) has launched Opto Assure, a new series of assays designed to enhance cell line development for biotherapeutics. The first assay allows for early detection of product aggregates, which accelerates the ramp-up to volume production. It enables manufacturers to select clonal cell lines with better yield and quality, reducing scale-up costs. The technology aims to minimize risks of late-stage failures associated with complex antibody formats, thus improving overall drug manufacturability and safety.
Berkeley Lights (Nasdaq: BLI) announced participation in the KeyBanc Life Sciences & MedTech Investor Forum. The management will engage in a fireside chat on March 24, 2021, at 7:45 a.m. Pacific Time. Interested parties can access a live and archived webcast through the company’s website.
Berkeley Lights specializes in Digital Cell Biology, focusing on the development of biotherapeutics and cell-based products. Their platform captures extensive data on single cells, aiming to standardize rapid functional characterization.
Berkeley Lights, a leader in Digital Cell Biology, reported a 31% revenue increase in Q4 2020, totaling $21.7 million, and a 13% rise for the full year to $64.3 million. The company expanded its installed base by 56%, reaching 75 platforms. Notable achievements include launching six new workflows and plans for the Opto Plasma B Discovery 4.0. Despite growth, the company faced operational losses of $11.8 million in Q4 and a net loss of $41.6 million for the year. Looking ahead, Berkeley Lights forecasts 2021 revenue between $90 million and $100 million, representing a 40% to 56% growth from 2020.
Berkeley Lights, a leader in Digital Cell Biology, will participate in the Cowen 41st Annual Healthcare Conference on March 4 at 11:10 a.m. PT. The management will engage in a fireside chat, providing insights into the company's advancements in biotherapeutics and cell-based products. Interested stakeholders can access a live and archived webcast of the presentation on their official website. Berkeley Lights is known for its innovative platform that enhances the development and commercialization of biotherapeutics through advanced automation and analysis of single cells.
Berkeley Lights (Nasdaq: BLI) announced key executive appointments as part of its organizational updates. Kurt Wood, previously Vice President of Business Development, has been appointed Chief Financial Officer, effective March 15, 2021. Peter Leddy joins as Chief Human Resources Officer, and Mimi Healy is appointed Chief Products Officer. The company is set to report its fourth quarter and year-end 2020 financial results on February 25, 2021. These leadership changes are anticipated to support Berkeley Lights' strategic objectives and growth in the Digital Cell Biology sector.
Berkeley Lights, Inc. (Nasdaq: BLI) has launched the Opto Plasma B Discovery 4.0 workflow, enhancing antibody discovery by enabling the transition from B cells to lead molecules in just one week. This advanced workflow allows customers to sample up to 100,000 cells, conduct sensitive cell-based assays, and recover sequences without costly synthesis. It targets complex molecules like GPCRs and Ion Channels. With rapid re-expression of over a thousand antibodies in a week, it reduces associated costs and labor. CEO Eric Hobbs stated that this development meets urgent customer demands in therapeutic discovery.
Berkeley Lights, a leader in Digital Cell Biology, will participate in the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 12, 2021, at 11:00 a.m. PT / 2:00 p.m. ET. A live and archived webcast of the presentation can be accessed through the company’s website. The company focuses on accelerating the development of biotherapeutics and cell-based products through its platform that captures phenotypic and genotypic information from single cells.
FAQ
What is the market cap of bli (bli)?
What does Berkeley Lights, Inc. do?
Who are the customers of Berkeley Lights?
What is OptoSelect™ technology?
Has Berkeley Lights achieved any recent milestones?
What are Berkeley Lights' current projects?
How is Berkeley Lights performing financially?
Where is Berkeley Lights headquartered?
What impact does Berkeley Lights have on the biotechnology sector?
What is the significance of their technology in biopharma?
Who are some of Berkeley Lights' strategic partners?
